Table 1.

Overview of important (chemo)radiotherapy de-escalation trials in which the radiation dose/volume was de-escalated. CRT = chemoradiation, RT = radiotherapy, OS = overall survival, PFS = progression-free survival, LRC = local/locoregional control, DMFS = distant metastasis-free survival.

Study	# Patients	Phase	Study Arm(s)	Results
Chera et al. [8,9]	44	II	RT (60 Gy) + cisplatin (30 mg/m2 weekly)	3-year LRC 100% 3-year DMFS 100% 3-year OS 95%
NRG-HN002 [6,10]	306	II	RT (60 Gy) + cisplatin vs. RT (60 Gy)	2-year PFS 90.5% (RT + cisplatin) vs. 87.6% (RT) 2-year OS 96.7% (RT + cisplatin) vs. 97.3% (RT)
MC1273 [11]	80	II	Adjuvant RT (30 Gy in 1,5 Gy twice per day or 36 Gy in 1,8 Gy twice per day)	2-year LRC 96.2% 2-year PFS 91.1% 2-year OS 98.7%
ECOG 3311 (ASCO abstract [12])	519	II	Depending on the risk profile after resection: Regular aftercare (low-risk, group A), randomization between adjuvant RT with 50 Gy (group B) or 60 Gy (group C) (intermediate-risk), additive cisplatin-based CRT (66 Gy) (high-risk, group D)	2-year PFS Group A: 93.9% Group B: 95.0% Group C: 95.9% Group D: 90.5%
AVOID [13]	60	II	Omission of the postoperative RT for the primary tumor site	2-year LRC 98.3% 2-year PFS 92.1% 2-year OS 100%